This is the authors' abstract. We don't add key points for this paper.
Despite advances in breast cancer therapy, its metastasis, particularly to bone, remains a significant challenge. Chemotherapeutic treatment with doxorubicin (DOX) elevates the circulating levels of TGF-β, potentially exacerbating bone metastasis. Moreover, DOX possesses several limitations, such as cardiotoxicity, rapid clearance, and multidrug resistance. Combinatorial therapy utilizing a (transforming growth factor) TGF-β inhibitor along with DOX could substantially reduce the metastatic burden. Baicalein (BAC), a key flavonoid, inhibits the TGF-β signaling pathway, potentially decreasing the bone metastatic ability of DOX. However, BAC is limited by poor solubility, low bioavailability, and a short half-life. Despite these challenges, a low combination index at a molar weight ratio of 1:4 (DOX:BAC) confirmed the synergistic potential of the combination. To deliver the ratiometric dose of both drugs, a PEGylated liposomal formulation loaded with DOX and BAC was developed using the ethanol injection method and evaluated for its anticancer and antimetastatic potential. The particle size of 132.53 ± 1.42 nm with narrow polydispersity and a ζ potential of -26.83 ± 2.2 mV were obtained for the developed nanoliposomes. The ratiometric combination loaded within the liposomal delivery carrier exhibited maximum synergistic activity in the syngeneic 4T1 BALB/c mice tumor model when administered intravenously through the tail vein. Moreover, the liposomal delivery vehicle showed a higher binding affinity toward hydroxyapatite, demonstrating selective bone accumulation. The results indicated efficient targetability and retention at the tumor site, as confirmed by pharmacokinetic profiling. Furthermore, micro-CT analysis revealed the preservation of bone architecture and minimal skeletal damage in treated groups. There was a 4.5-fold increase in the percent bone volume/total volume after treatment with nanoliposomes. These results highlight the promising therapeutic potential of combinatorial DOX and BAC delivery in the treatment of breast cancer-induced bone metastasis.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Yadav et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: